Show simple item record

dc.contributor.authorNic Lochlainn, Laura M
dc.contributor.authorde Gier, Brechje
dc.contributor.authorvan der Maas, Nicoline
dc.contributor.authorvan Binnendijk, Rob
dc.contributor.authorStrebel, Peter M
dc.contributor.authorGoodman, Tracey
dc.contributor.authorde Melker, Hester E
dc.contributor.authorMoss, William J
dc.contributor.authorHahné, Susan J M
dc.date.accessioned2019-10-03T11:15:26Z
dc.date.available2019-10-03T11:15:26Z
dc.date.issued2019-09-20
dc.identifier.issn1474-4457
dc.identifier.pmid31548081
dc.identifier.doi10.1016/S1473-3099(19)30396-2
dc.identifier.urihttp://hdl.handle.net/10029/623256
dc.description.abstractOur search retrieved 1156 records and 85 were excluded due to duplication. 1071 records were screened for eligibility, of which 351 were eligible for full-text screening and 21 were eligible for inclusion in the review. From 13 studies, the pooled proportion of infants seropositive after two MCV doses, with MCV1 administered before 9 months of age, was 98% (95% CI 96-99; I2=79·8%, p<0·0001), which was not significantly different from seropositivity after a two-dose MCV schedule starting later (p=0·087). Only one of four studies found geometric mean titres after MCV2 administration to be significantly lower when MCV1 was administered before 9 months of age than at 9 months of age or later. There was insufficient evidence to determine an effect of age at MCV1 administration on antibody avidity. The pooled vaccine effectiveness estimate derived from two studies of a two-dose MCV schedule with MCV1 vaccination before 9 months of age was 95% (95% CI 89-100; I2=12·6%, p=0·29). Seven studies reporting on measles virus-specific cellular immune responses found that T-cell responses and T-cell memory were sustained, irrespective of the age of MCV1 administration. Overall, the quality of evidence was moderate to very low.en_US
dc.language.isoenen_US
dc.titleEffect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis.en_US
dc.identifier.journalLancet Infect Dis 2019; 19(11):1246-54en_US
dc.source.journaltitleThe Lancet. Infectious diseases


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record